AR071518A1 - Derivados de arilpirazinona como estimulantes de la secrecion de insulina metodos para obtenerlos y su uso para el tratamiento de diabetes - Google Patents
Derivados de arilpirazinona como estimulantes de la secrecion de insulina metodos para obtenerlos y su uso para el tratamiento de diabetesInfo
- Publication number
- AR071518A1 AR071518A1 ARP090101517A ARP090101517A AR071518A1 AR 071518 A1 AR071518 A1 AR 071518A1 AR P090101517 A ARP090101517 A AR P090101517A AR P090101517 A ARP090101517 A AR P090101517A AR 071518 A1 AR071518 A1 AR 071518A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- hydrogen
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de arilpirazinona de la formula en donde: (1) R1 está seleccionado de Z; R2 está seleccionado de hidrogeno, alquilo, cicloalquilo; R3 está seleccionado de hidrogeno, halogeno, alquilo, cicloalquilo; A está seleccionado de arilo, heteroarilo, arilalquilo, en donde los grupos alquilo, arilo y heteroarilo pueden estar opcionalmente sustituidos con uno o varios sustituyentes seleccionados de Y; Z es: alquilo, alquenilo, alquinilo, alcoxialquilo, arilo, arilalquilo, ariloxialquilo, arilalcoxialquilo, ariltioalquilo, arilalquiltioalquilo, heteroarilalquilo, heteroariloxialquilo, heteroarilalcoxialquilo, heteroariltioalquilo, heteroarilalquiltioalquilo, heterocicloalquilo, heterocicloalquilalquilo, heterocicloalquiloxialquilo, heterocicloalquilalcoxialquilo, heterocicloalquiltioalquilo, heterocicloalquilalquiltioalquilo, arilalquenilo, arilalquinilo, cicloalquilo, cicloalquilalquilo, cicloalquiloxialquilo, cicloalquilalcoxialquilo, cicloalquiltioalquilo, cicloalquilalquiltioalquilo, cada uno de estos grupos puede estar opcionalmente sustituido con uno o varios sustituyentes seleccionados de Y; Y es: hidroxi, tio, halogeno, ciano, trifluorometoxi, trifluorometilo, carboxi, carboximetilo, carboxietilo, alquilo, alcoxi, alquilamino, arilo, arilsulfonilalquilo, ariloxi, arilalcoxi, amino, NR5R6, azido, nitro, guanidino, amidino, fosfono, oxo, carbamoílo, alquilsulfonilo, alquilsulfinilo, alquiltio, SF5, dos grupos Y pueden formar un metilendioxi; R5 y R6 están seleccionados, de modo independiente, de hidrogeno, alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, en donde los grupos alquilo, arilo y heteroarilo pueden estar opcionalmente sustituidos con uno o varios sustituyentes seleccionados de Y, R5 y R6 pueden constituir juntos un heterociclo; R2 y R3 pueden constituir un ciclo que corresponde a la formula general (2) R1 y A se definen como con anterioridad; n = 3, 4, 5; R4 representa uno o varios sustituyentes seleccionados de hidrogeno, alquilo, alcoxi, cicloalquilo, arilo, en donde los grupos alquilo, cicloalquilo y arilo pueden estar opcionalmente sustituidos con uno o varios sustituyentes, seleccionados de hidroxi, halogeno, alquilo, alcoxi, trifluorometoxi, trifluorometilo, alquilsulfonilo, NR7R8; R7 y R8 están seleccionados, de modo independiente, de hidrogeno, alquilo, cicloalquilo; así como sus formas racémicas, tautomeros, enantiomeros, diastereomeros, epímeros y polimorfos y mezclas de ellos y sus sales farmacéuticamente aceptables. Como estimulantes de la secrecion de insulina. También se provee la preparacion y al uso de estos derivados de pirazinona para la prevencion y/o el tratamiento de diabetes y patologías asociadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08008165 | 2008-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071518A1 true AR071518A1 (es) | 2010-06-23 |
Family
ID=40589704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101517A AR071518A1 (es) | 2008-04-29 | 2009-04-29 | Derivados de arilpirazinona como estimulantes de la secrecion de insulina metodos para obtenerlos y su uso para el tratamiento de diabetes |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8815859B2 (es) |
| EP (1) | EP2268624B1 (es) |
| JP (1) | JP5498482B2 (es) |
| KR (1) | KR101687419B1 (es) |
| CN (1) | CN102015661B (es) |
| AR (1) | AR071518A1 (es) |
| AU (1) | AU2009242720B2 (es) |
| BR (1) | BRPI0910833A2 (es) |
| CA (1) | CA2722813C (es) |
| CO (1) | CO6310997A2 (es) |
| CY (1) | CY1114531T1 (es) |
| DK (1) | DK2268624T3 (es) |
| EA (1) | EA022345B1 (es) |
| EC (1) | ECSP10010642A (es) |
| ES (1) | ES2433210T3 (es) |
| HR (1) | HRP20130992T1 (es) |
| IL (1) | IL208959A (es) |
| MX (1) | MX2010011792A (es) |
| NZ (1) | NZ589555A (es) |
| PL (1) | PL2268624T3 (es) |
| PT (1) | PT2268624E (es) |
| SI (1) | SI2268624T1 (es) |
| UA (1) | UA103191C2 (es) |
| WO (1) | WO2009132739A1 (es) |
| ZA (1) | ZA201008505B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010034671A1 (en) * | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyrine or pyrazine derivatives for treating hcv |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013066838A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| CN104628661A (zh) * | 2015-02-05 | 2015-05-20 | 北京理工大学 | 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途 |
| CN114907323B (zh) * | 2022-05-31 | 2023-08-15 | 内蒙古民族大学 | 喹喔啉酮类化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62198671A (ja) * | 1986-02-25 | 1987-09-02 | Toyo Jozo Co Ltd | １−置換アルキル１，２−ジヒドロ−２−ピラジノン誘導体 |
| SK13752003A3 (en) * | 2001-05-14 | 2004-11-03 | Bristol Myers Squibb Pharma Co | Substituted pyrazinones, pyridines and pyrimidines as ligands of factor releasing corticotropine |
| ES2281666T3 (es) | 2002-07-19 | 2007-10-01 | Biovitrum Ab | Novedosos derivados de piperazinil-pirazinona para el tratamiento de los desordenes relacionados con el receptor 5-ht2a. |
| FR2857867B1 (fr) * | 2003-07-25 | 2005-10-14 | Oreal | Utilisation en coloration capillaire de derives de ninhydrine portant un groupe heteroalkyle |
| WO2005097136A1 (en) * | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Biaryl substituted pyrazinones as sodium channel blockers |
| WO2006050506A1 (en) * | 2004-11-03 | 2006-05-11 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| TW200640881A (en) * | 2005-02-15 | 2006-12-01 | Du Pont | Fungicidal pyrazine derivatives |
| RU2008129679A (ru) | 2005-12-21 | 2010-01-27 | Янссен Фармацевтика Н.В. (Be) | Новые замещенные пиразиноновые производные для применения при мсн-1-опосредованных заболеваниях |
| EP2034993A2 (en) * | 2006-06-21 | 2009-03-18 | E.I. Du Pont De Nemours And Company | Pyrazinones as cellular proliferation inhibitors |
-
2009
- 2009-03-31 BR BRPI0910833-5A patent/BRPI0910833A2/pt not_active IP Right Cessation
- 2009-03-31 CN CN200980114790.3A patent/CN102015661B/zh not_active Expired - Fee Related
- 2009-03-31 WO PCT/EP2009/002328 patent/WO2009132739A1/en active Application Filing
- 2009-03-31 KR KR1020107026410A patent/KR101687419B1/ko active IP Right Grant
- 2009-03-31 NZ NZ589555A patent/NZ589555A/xx not_active IP Right Cessation
- 2009-03-31 JP JP2011506584A patent/JP5498482B2/ja active Active
- 2009-03-31 EA EA201001688A patent/EA022345B1/ru not_active IP Right Cessation
- 2009-03-31 PL PL09737783T patent/PL2268624T3/pl unknown
- 2009-03-31 CA CA2722813A patent/CA2722813C/en not_active Expired - Fee Related
- 2009-03-31 MX MX2010011792A patent/MX2010011792A/es active IP Right Grant
- 2009-03-31 DK DK09737783.2T patent/DK2268624T3/da active
- 2009-03-31 ES ES09737783T patent/ES2433210T3/es active Active
- 2009-03-31 PT PT97377832T patent/PT2268624E/pt unknown
- 2009-03-31 US US12/990,098 patent/US8815859B2/en active Active
- 2009-03-31 SI SI200930752T patent/SI2268624T1/sl unknown
- 2009-03-31 UA UAA201014234A patent/UA103191C2/ru unknown
- 2009-03-31 EP EP09737783.2A patent/EP2268624B1/en active Active
- 2009-03-31 AU AU2009242720A patent/AU2009242720B2/en not_active Ceased
- 2009-04-29 AR ARP090101517A patent/AR071518A1/es unknown
-
2010
- 2010-10-25 CO CO10131722A patent/CO6310997A2/es not_active Application Discontinuation
- 2010-10-26 IL IL208959A patent/IL208959A/en not_active IP Right Cessation
- 2010-11-26 EC EC2010010642A patent/ECSP10010642A/es unknown
- 2010-11-26 ZA ZA2010/08505A patent/ZA201008505B/en unknown
-
2013
- 2013-10-21 HR HRP20130992AT patent/HRP20130992T1/hr unknown
- 2013-10-25 CY CY20131100943T patent/CY1114531T1/el unknown
-
2014
- 2014-07-22 US US14/337,796 patent/US9233937B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070635A1 (es) | DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS. | |
| AR070797A1 (es) | Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes | |
| AR070798A1 (es) | Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes | |
| AR070796A1 (es) | Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CY1118723T1 (el) | Ενωσεις βενζοθειαζολιου και αζαβενζοθειαζολιου χρησιμες ως αναστολεiς κινασης | |
| AR071518A1 (es) | Derivados de arilpirazinona como estimulantes de la secrecion de insulina metodos para obtenerlos y su uso para el tratamiento de diabetes | |
| EA201170196A1 (ru) | Производные бензазепинов и их применение в качестве h3 гистаминовых антагонистов | |
| PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
| RU2016146365A (ru) | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| AR061372A1 (es) | Amino-imidazoles y sus usos como medicamentos para el tratamiento de mal de alzheimer, demencia y neurodegeneracion | |
| HRP20080541T3 (en) | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases | |
| AR059249A1 (es) | Compuesto amina trisustituido | |
| PE20142019A1 (es) | Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40 | |
| AR076098A1 (es) | Derivados de benzofurano | |
| CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
| AR075022A1 (es) | Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1) | |
| AR067996A1 (es) | Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros. | |
| AR075635A1 (es) | N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos | |
| PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |